We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Successful Transport of Blood Samples with Small Drones

By LabMedica International staff writers
Posted on 17 Aug 2015
Image: Preparation of clinical blood samples for test-flights by small drone. (1) Left: Custom-cut foam block. (2) Right: Placement of sealed foam lock in the bio-hazard bags as well as absorbent material for potential sample containment (Photos courtesy of Johns Hopkins Medicine and PLOS One).
Image: Preparation of clinical blood samples for test-flights by small drone. (1) Left: Custom-cut foam block. (2) Right: Placement of sealed foam lock in the bio-hazard bags as well as absorbent material for potential sample containment (Photos courtesy of Johns Hopkins Medicine and PLOS One).
Image: (3) Left: Placement of first bio-hazard bag inside the second bio-hazard bag. (4) Middle-right: Placement of double-wrapped payload in the fuselage (Photo courtesy of Johns Hopkins Medicine and PLOS One).
Image: (3) Left: Placement of first bio-hazard bag inside the second bio-hazard bag. (4) Middle-right: Placement of double-wrapped payload in the fuselage (Photo courtesy of Johns Hopkins Medicine and PLOS One).
Image: (5) Left: Covered, secured, and labeled fuselage. (6) Right: Launch with hand toss (Photo courtesy of Johns Hopkins Medicine and PLOS One).
Image: (5) Left: Covered, secured, and labeled fuselage. (6) Right: Launch with hand toss (Photo courtesy of Johns Hopkins Medicine and PLOS One).
A proof-of-concept, initial study has shown that small unmanned aerial systems (UAS) could potentially be used to transport clinical blood specimens for diagnostics without damage to the specimens.

In a first rigorous examination published about the impact of drone transport on biological samples, a team of clinical researchers and engineers, led by Timothy Kien Amukele, MD, PhD, pathologist at Johns Hopkins University School of Medicine (Baltimore, MD, USA) and director of a collaboration with Makerere University in Uganda, found that results of common, routine tests on the blood samples were not affected by up to 40 minutes of sample-travel in hobby-sized drones. This could especially aid millions of people in developing nations where most tests are currently done by dedicated laboratories that can be scores of miles from remote clinics in rural and economically impoverished areas that lack, for example, good roads.

“Biological samples can be very sensitive and fragile,” said Dr. Amukele. That sensitivity makes even the pneumatic-tube systems used by many hospitals, for example, unsuitable for transporting blood for certain purposes. Of particular concern related to sample transport in drones is the sudden acceleration that marks the launch of the vehicle and the jostling when the drone lands on its belly. “Such movements could have destroyed blood cells or prompted blood to coagulate and I thought all kinds of blood tests might be affected, but our study shows they weren’t,” he added.

For the study, total of 6 blood samples were collected from each of 56 healthy adult volunteers at Johns Hopkins Hospital. Samples were driven to a flight site an hour’s drive from the hospital on days when the temperature was moderate. There, half the samples were held stationary (non-flight); the other half were packaged for protection during the in-flight environment and to prevent leakage, then loaded into a hand-launched fixed-wing drone and flown for periods of 6–38 minutes. Owing to Federal Aviation Administration (FAA) rules, the flights were conducted in an unpopulated area, kept below 100 meters and in the line-of-sight of the certified drone pilot.

Samples were driven back from the flight-field to the Johns Hopkins Hospital Core Laboratory, where 33 of the most common chemistry, hematology, and coagulation tests were performed (tests that together account for around 80% of all such tests performed), including for sodium, glucose, and red blood cell count.

Comparing lab results of the flown vs. non-flown samples from each volunteer showed that these flights essentially had no impact, although the precision of one blood test—for total carbon dioxide (the bicarbonate test)—did differ for some samples pairs. This may be because the blood sat for up to 8 hours before being tested, but whether the out-of-range results were due to this time lag or to the drone transport is unknown. Nevertheless, there were no consistent differences in results between the flown vs. non-flown blood.

“The ideal way to test that would be to fly the blood around immediately after drawing it, but neither the FAA nor Johns Hopkins would like drones flying around the hospital,” said Dr. Amukele.

The likely next step is a pilot study in Africa where clinics are sometimes 60 or more miles away from labs. “A drone could go 100 km in 40 minutes,” said Dr. Amukele, “They’re less expensive than motorcycles, are not subject to traffic delays, and the technology already exists for the drone to be programmed to “home” to certain GPS coordinates, like a carrier pigeon.”

Drones have already been tested as carriers of medicines to clinics in remote areas, but whether and how drones will be used to carry medicines and potentially infectious patient specimens over more populated areas will depend on laws and regulations.

The study, by Amukele TK, et al, was published July 29, 2015, in the journal PLOS One.

Related Links:

Johns Hopkins University School of Medicine


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Clinical Chemistry Assay
Sorbitol Dehydrogenase (SDH)
Japanese Encephalitis Test
Japanese Encephalitis Virus Real Time PCR Kit
New
Microbiology Laboratory Automation Solution
BD Kiestra™ ReadA+BarcodA

Channels

Clinical Chemistry

view channel
Image: A large, international study led by City of Hope found that the new, investigational liquid biopsy, called PANXEON, was highly sensitive in detecting stage 1 and 2 pancreatic cancer and had a low rate of false positives. The test was also able to identify high-grade dysplasia, a precancerous condition of the pancreas, potentially enabling intervention before cancer develops. (Photo courtesy of City of Hope)

Multi-Biomarker Blood Test Shows Promise for Early Pancreatic Cancer Detection

Pancreatic cancer has the lowest survival rates of any cancer, with only 14% of patients alive five years after diagnosis. The disease is typically discovered after it has spread, and an estimated 90%... Read more

Immunology

view channel
Image: Although many people harbor latent Epstein-Barr virus (EBV), growing evidence has linked the virus to MS pathobiology (Image Credit: Adobe Stock)

Blood EBV Activity Biomarkers May Predict Multiple Sclerosis Relapse Months Ahead

Predicting relapse in multiple sclerosis (MS) remains difficult, limiting opportunities for timely intervention and monitoring. Although many people harbor latent Epstein-Barr virus (EBV), growing evidence... Read more

Microbiology

view channel
Image: Graphical Abstract (Jose A. Céspedes, Maria I. Montañez, Isabel M. Jiménez, et al. Magnetic nanoparticles enable clinically relevant in vitro diagnosis of beta-lactam allergy. Materials Today Bio (2026). DOI: 10.1016/j.mtbio.2026.103356)

Magnetic Nanoparticles Enable More Sensitive Beta-Lactam Allergy Testing

Penicillin allergy labels are common in clinical practice, yet many are incorrect and can lead to suboptimal antibiotic choices. Although 8%–25% of people report a penicillin allergy, only 1%–10% are truly... Read more

Pathology

view channel
image Credit: iStock

Tumor Budding Grading May Predict Chemotherapy Benefit in Resected Lung Squamous Cancer

Outcomes after resection for lung squamous cell carcinoma (SqCC) vary substantially, and the uneven benefit of adjuvant chemotherapy complicates postsurgical treatment decisions. Pathologic markers that... Read more

Industry

view channel
Image: The acquisition adds Convergent Genomics’ UroAmp platform and proprietary urinary tumor DNA technology to Veracyte’s portfolio (Photo courtesy of Convergent Genomics)

Veracyte Acquisition Expands Urine-Based Bladder Cancer Monitoring Capabilities

Veracyte, Inc. has acquired Convergent Genomics, expanding its urology diagnostics offerings with the company’s UroAmp platform and proprietary urinary tumor DNA (utDNA) technology. UroAmp has been clinically... Read more